Deborah Cooper

Two music tech titans are betting that gamified lessons and connected keyboards can solve the age-old problem of why so many of us quit our musical dreams.

A Dell award for Unisys is more than a headline. It's a signpost for how enterprises must rebuild their digital foundations in the face of the AI revolution.

With foreign ownership now over 51%, a look at how South Korea's KT&G is attracting giants like BlackRock through performance, policy, and a surprising ESG edge.

A new partnership between health tech pioneer Snke and biotech firm Precision NeuroMed aims to build a data-driven roadmap for treating neurological diseases.

A new deal between L’Oréal and GXO isn't just about logistics. It’s a blueprint for the future of retail, sustainability, and regional economic growth.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

Wells Fargo and Urban Strategies Inc. are betting $1.2M on a new model for urban renewal, one that trusts local entrepreneurs to rebuild their own communities.

Amid a critical talent shortage, an Arizona luxury club and a culinary giant are reviving the apprenticeship, blending paid work with global training to build trust.

AMR Clinical's appointment of Bernard Dyson as CFO is more than a leadership change. It's a strategic move to navigate a complex industry and scale its patient-centric model.

Salesforce's new autonomous 'Agentforce' promises a revolution in digital labor, but how do you govern an AI that thinks for itself? A new DevOps model emerges.

ACORE CAPITAL's hire of a top marketing veteran isn't just a new title. It's a strategic play in a world where private credit giants must now win hearts and minds, not just deals.

A new clinical trial for a sacroiliac joint device isn't just about technology; it's about a company's bet that rigorous evidence is the best medicine for patients and the healthcare system.

Millions suffer from Dry Eye Disease with few good options. A new clinical trial is now testing a drug tailored to a patient's DNA. Is this the end of trial-and-error?

Yoichi Hori now leads both U.S. and Canadian operations, a move signaling a unified continental strategy aimed at accelerating electrification and growth.

Renowned jurist and human rights champion Louise Arbour assumes the role of Governor General, bringing an unprecedented legacy of international justice to the role.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

With Brian Ewart's appointment as General Counsel, the nonprofit signals a new era of disciplined growth, leveraging top legal talent to navigate complex federal contracts.

Mill Point Capital's 20th carve-out acquires TSSS, reshaping the industrial MRO market. A deep dive into the strategy, the players, and the future of trust.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?